The End of Alzheimer’s Program – Dale E. Bredesen, M.D. References

Following is a list of references from the book, The End of Alzheimer’s Program, published by Avery/Random House. Due to the length of the text, these references could not be included in the print version, and therefore are listed below. 

80 – Innocent Mupunga et al., Journal of Food Protection 77, no. 10, 1814–18, October 2014

Natural Occurrence of Aflatoxins in Peanuts and Peanut Butter from Bulawayo, Zimbabwe

81 – Toni I. Pollin and Michael Quartuccio, Current Nutrition Reports 2, no. 4, 236–42, December 2013

What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation?

82 – Christopher E. Ramsden et al., BMJ 353, i1246, April 2016

Re-Evaluation of the Traditional Diet-Heart Hypothesis: Analysis of Recovered Data from Minnesota Coronary Experiment (1968-73)

82 – James E. Dalen and Stephen Devries, American Journal of Medicine 127, no. 5, 364–69, December 2013

Diets to Prevent Coronary Heart Disease 1957–2013: What Have We Learned?

83 – Amit Sachdeva et al., American Heart Journal 157, no. 1, 111–17.e2, January 2009

Lipid Levels in Patients Hospitalized with Coronary Artery Disease: An Analysis of 136,905 Hospitalizations in Get With the Guidelines

84 – Jennifer S. Lee et al., Diabetes Care 40, no. 4, 529–37, January 2017

Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study

85 – J. Michael Gaziano et al., Circulation 96, no. 8, 2520–25, October 1997

Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction

86 – K. T. Khaw et al., ACC Current Journal Review 13, no. 12, 413–20, December 2004

Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk

87 – Olivier Descamps et al., Journal of Alzheimer’s Disease 25, no. 1, 51–57, March 2011

Induction of the C-Terminal Proteolytic Cleavage of AβPP by Statins

87 – US Food and Drug Administration, last modified January 19, 2016

FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs